A race is shaping up among drug manufacturers that are vying to roll out better options when it comes to weight-loss drugs.
Read More
At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly and Co. asserted its dominance in the weight-loss market.
Read More
After transforming the treatment of diabetes and weight loss, a growing body of research is raising the possibility that these drugs may help protect against cancer.
The company, which is owned by biopharmaceutical giant Bristol Myers Squibb Co., is working on an incentive package with Whitestown officials that includes tax abatements for construction and new equipment for two buildings.
Eli Lilly and Co. this month unveiled startling new data for an experimental weight-loss drug. The breakthrough also is prompting some doctors to urge caution.
Tens of millions of people are now taking the medications worldwide, turning what began as obesity and diabetes treatments into what could be modern medicine’s largest unplanned neuroscience experiments.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
The case against Lilly centered on the rebates that drug companies must pay to state Medicaid programs to subsidize some of the cost.
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
The move comes as Lilly has embarked on a spree of large acquisitions, including two of its most-expensive transactions ever.
Demand for drugs to combat ticks and other pests was a major factor boosting Elanco Animal Health Inc.’s first quarter results, company executives said Wednesday.
Lilly’s latest commitment at the LEAP District brings the company’s total investment there since 2022 to $18 billion.
The potential savings estimated would be substantial as Americans spent $467 billion on prescription drugs in 2024, according to the most recent government data available.
The settlement is among the largest in a series of settlements by drugmakers, wholesalers and pharmacies in recent years.
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs that remain illegal under federal law.
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
The judge had been expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government.
The criminal sentence Tuesday will mark a major step toward the company finalizing a settlement of thousands of lawsuits it faces over the toll of opioids.
